IMMUNE AND INFLAMATORYRESPONSE HETEROGENEITY IN NEUROBLASTOMA Nöroblastomda immun ve inflamatuar cevapta heterojenite


Aktaş T. Ç., Kızmazoğlu D., Aktaş S., Serinan E. Ö., Çeçen R. E., İnce D., ...Daha Fazla

VII.Turkey in vitro Diagnostic Symposia: Inflammation, İzmir, Türkiye, 27 - 29 Nisan 2022, cilt.34, ss.25

  • Yayın Türü: Bildiri / Özet Bildiri
  • Cilt numarası: 34
  • Doi Numarası: 10.1515/tjb-2022-47s105
  • Basıldığı Şehir: İzmir
  • Basıldığı Ülke: Türkiye
  • Sayfa Sayıları: ss.25
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objectives: Immunity and inflammatory response are the most important features in cancer development, progression, and survival. Prognostic significance of immune and inflammationrelated markers in neuroblastoma before and after treatment and during the follow-up period has not been adequately investigated. The aim of this study is to investigate the prognostic importance of immune and inflammation-related markers in neuroblastoma. Materials-Methods: In 1750 neuroblastoma cases examined between 2012-2022, achievable blood albumin, CRP values and ratio (Glascow Prognostic score), diversity and amount of immune cell infiltration in tumor tissue and surrounding tissue, immunohistochemical CTLA-4, PDL-1, PD-1, PDL-2 expression was evaluated. RESULTS were tested with analysis of variance and survival at p<0.05 significance. Results: The mean age of the cases was 36.23±39.90 (1-217 months) and 48.6% were girls and 51.4% were boys. 28% of the cases are in low risk, 23.3% in medium risk, 48.7% in high-risk class. Lymphocyte infiltration was detected in 6% and a low number in neuroblastoma cases before treatment. No heterogeneity was detected in the expression of CTLA-4, PDL1, PD1. After multimodal chemotherapy, lymphocyte infiltration was found significantly more in tissues with differentiated ganglioneuroma. It was noted that immunity did not show intertumoral heterogeneity. Conclusions: Neuroblastoma was found to be weak in immune and inflammatory response. Absence of intratumoral heterogeneity in immune response, increased immune cell increase after chemotherapy were interpreted in favor of metachronous immune heterogeneity. In vitro, ex vivo and in vivo studies are needed to determine the immune profile changes in tumors after radiotherapy and chemotherapy, in short, whether neuroblastomas can be converted from cold tumors to hot tumors for immunotherapy. Keywords: Neuroblastoma, heterogeneity, immune response, inflamatory response